Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Wong, Ann ^a   Lim, Jing ^a   Sinha, Arvind ^a   Gopinathan, Anil ^a   Lim, Robert ^a   Tan, Chee Seng ^a   Soh, Thomas ^a   Venkatesh, Sudhakar ^a   Titin, Christina ^a   Sapari, Sabrina ^b   Lee, Soo Chin ^a,b   Yong, Wei Peng ^a,b   Tan, Ping ^a,b   Pang, Brendan ^a,b   Wang, Ting Ting ^b   Zee, Ying Kiat ^a   Soong, Richie ^a,b   Trnkova, Zuzana ^c   Lathia, Chetan ^c   Thiery, Jean Paul ^b   Wilhelm, Scott ^c   Jeffers, Michael ^c   Goh, Boon Cher ^a,b   more..

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c BAYER CORPORATION   (United States)

Author keywords

Colorectal carcinoma; Pharmacodynamics; Plasma cell free DNA; Regorafenib

Indexed keywords

BEVACIZUMAB; CELL DNA; CETUXIMAB; FLUORODEOXYGLUCOSE; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PODOPLANIN; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; REGORAFENIB; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; VASCULOTROPIN RECEPTOR 2; CARBANILAMIDE DERIVATIVE; DNA; PIK3CA PROTEIN, HUMAN; PYRIDINE DERIVATIVE; TUMOR MARKER;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BRAF GENE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COLORECTAL CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DNA DETERMINATION; DOWN REGULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG TUMOR LEVEL; DRUG WITHDRAWAL; FATIGUE; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE IDENTIFICATION; GENETIC MARKER; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTENTION TO TREAT ANALYSIS; INTESTINE PERFORATION; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; PHARMACODYNAMICS; PHARMACOGENETICS; PIK3CA GENE; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE STUDY; SOMATIC MUTATION; SPEECH DISORDER; TUMOR BIOPSY; UPREGULATION; BLOOD; CELL FREE SYSTEM; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DEMOGRAPHY; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; BIOMARKERS, TUMOR; CELL-FREE SYSTEM; COLORECTAL NEOPLASMS; DEMOGRAPHY; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEOMICS; PYRIDINES; TREATMENT OUTCOME;

EID: 84924283696     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0405-4     Document Type: Article

References (15)

1. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245-55.
2. Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2012;381(9863):303-12.
3. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985-90.
4. Lee J, Kim S, Kim P, Liu X, Lee T, Kim K-M, et al. A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. PLoS One. 2013;8(1):e54644.
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54.
6. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz Jr S, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005;41(11):1649-54.
7. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525-32.
8. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532-6.
9. de Martino M, Klatte T, Haitel A, Marberger M. Serum cell-free DNA in renal cell carcinoma. Cancer. 2012;118(1):82-90.
10. Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res. 2010;38(18):6159-75.
11. Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199-209.
12. Duncan James S, Whittle Martin C, Nakamura K, Abell Amy N, Midland Alicia A, Zawistowski Jon S, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 2012;149(2):307-21.
13. Carr BI, Cavallini A, Lippolis C, D'Alessandro R, Messa C, Refolo MG, et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol. 2013;228(2):292-7.
14. Carr BI, D'Alessandro R, Refolo MG, Iacovazzi PA, Lippolis C, Messa C, et al. Effects of low concentrations of Regorafenib and Sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. J Cell Physiol. 2013;228(6):1344-50.
15. Sajithlal GB, Hamed HA, Cruickshanks N, Booth L, Tavallai S, Syed J, et al. Sorafenib/Regorafenib and Phosphatidyl Inositol 3 Kinase/Thymoma viral proto-oncogene inhibition interact to kill tumor cells. Mol Pharmacol. 2013;84(4):562-71.